Literature DB >> 15530685

Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.

M Omori1, R Pu, T Tanabe, W Hou, J K Coleman, M Arai, J K Yamamoto.   

Abstract

Vaccine-induced T cell responses to FIV were assessed by measuring FIV-specific cytokine and cytotoxic-effector molecule production. A total of 22 cats at 10-12 weeks of age received either dual-subtype FIV vaccine (n=12), uninfected cell lysate (n=5) consisting of cells used to produce vaccine viruses, or no immunization (n=5). Significant increases in mRNA and protein production of T-helper 1 (Th1) cytokines (IL-2, IFNgamma), mRNA production of a cytotoxic-effector molecule (perforin), and lymphoproliferation response were observed in peripheral blood mononuclear cells (PBMC) from dual-subtype FIV-vaccinated cats after in vitro stimulation with inactivated FIV. In contrast, no statistically significant increase in FIV-stimulated mRNA production of Th2 cytokines (IL-4, IL-6) or other cytotoxic-effector molecules (TNFalpha, FasL) was observed in the PBMC from dual-subtype vaccinated cats. Moreover, no FIV-specific increases in the IFNgamma, IL-2, and perforin mRNA productions and in the IFNgamma bioactivity and lymphoproliferation responses were observed in the PBMC from cell-immunized cats. These observations suggest that IFNgamma induction, lymphoproliferation, and significant portion of IL-2 and perforin productions in the PBMC from dual-subtype vaccinated cats are clearly specific for viral antigens. Overall, dual-subtype FIV vaccine elicited strong Th1 response (IFN(, IL-2), which may contribute to the vaccine protection by enhancing the perforin-mediated cytotoxic-cell activity against FIV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530685     DOI: 10.1016/j.vaccine.2004.05.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Feline leukemia and feline immunodeficiency virus in Canada - A comment.

Authors:  Ed Doornenbal; Walt Ingwersen; Guillaume Cloutier
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008

Review 2.  Advances in FIV vaccine technology.

Authors:  Elizabeth W Uhl; Marcus Martin; James K Coleman; Janet K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2008-01-20       Impact factor: 2.046

3.  Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

Authors:  James K Coleman; Ruiyu Pu; Marcus M Martin; Ezra N Noon-Song; Raphael Zwijnenberg; Janet K Yamamoto
Journal:  Vaccine       Date:  2013-06-22       Impact factor: 3.641

Review 4.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

5.  Major Histocompatibility Complex Class I (FLA-E*01801) Molecular Structure in Domestic Cats Demonstrates Species-Specific Characteristics in Presenting Viral Antigen Peptides.

Authors:  Ruiying Liang; Yaping Sun; Yanjie Liu; Junya Wang; Yanan Wu; Zibin Li; Lizhen Ma; Nan Zhang; Lijie Zhang; Xiaohui Wei; Zehui Qu; Nianzhi Zhang; Chun Xia
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

6.  An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.

Authors:  Alek M Aranyos; Shannon R Roff; Ruiyu Pu; Jennifer L Owen; James K Coleman; Janet K Yamamoto
Journal:  Vaccine       Date:  2016-01-21       Impact factor: 3.641

7.  Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.

Authors:  Paweł M Bęczkowski; Matthew Harris; Navapon Techakriengkrai; Julia A Beatty; Brian J Willett; Margaret J Hosie
Journal:  Vaccine       Date:  2015-01-19       Impact factor: 3.641

Review 8.  Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.

Authors:  Bikash Sahay; Janet K Yamamoto
Journal:  Viruses       Date:  2018-05-22       Impact factor: 5.048

9.  Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.

Authors:  Bikash Sahay; Alek M Aranyos; Meerambika Mishra; Andrew C McAvoy; Marcus M Martin; Riuyu Pu; Sayaka Shiomitsu; Keijiro Shiomitsu; Michael J Dark; Missa P Sanou; Shannon R Roff; Mobeen H Rathore; Janet K Yamamoto
Journal:  Viruses       Date:  2019-02-03       Impact factor: 5.048

10.  Bimodal immunoglobulin A gammopathy in a cat with feline myeloma-related disorders.

Authors:  Masaya Igase; Takako Shimokawa Miyama; Satoshi Kambayashi; Yumiko Shimoyama; Hiroko Hiraoka; Yumi Hirata; Miki Iwata; Kenji Baba; Takuya Mizuno; Masaru Okuda
Journal:  J Vet Med Sci       Date:  2015-12-04       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.